Evommune EVMN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.65M+10.1% | $1.49M-11.8% | $1.69M-7.6% | $1.83M+15.2% | $1.59M-5.3% | ||
| $684.39K-16.9% | $823.77K+15.1% | $715.82K-17.2% | $864.44K+19.5% | $723.49K+4.8% | ||
| $961.13K+43.3% | $670.76K-31.4% | $978.35K+1.1% | $968.1K+11.7% | $866.76K-12.4% | ||
| 58.4%+13.5pp | 44.9%-12.9pp | 57.7%+4.9pp | 52.8%-1.7pp | 54.5%-4.4pp | ||
| $263.71K+55.2% | $169.87K+42.9% | $118.88K-28.0% | $165.04K-7.6% | $178.63K+46.9% | ||
| $1.38M-15.5% | $1.63M+74.2% | $937.76K-2.2% | $958.49K+33.1% | $720.23K-28.2% | ||
| $1.64M-8.8% | $1.8M+70.7% | $1.06M-6.0% | $1.12M+25.0% | $898.86K-20.1% | ||
| -$682.81K+39.7% | -$1.13M-1,347% | -$78.29K+49.6% | -$155.44K-384% | -$32.1K+76.4% | ||
| -41.5%+34.3pp | -75.8%-71.2pp | -4.6%+3.9pp | -8.5%-6.5pp | -2%+6.1pp | ||
| $25.8K-68.1% | $80.98K-47.9% | $155.31K+119% | $71.01K-25.3% | $95.09K-33.2% | ||
| -$6.99M-920% | $852.32K+229% | $259K— | —— | -$126.78K+54.4% | ||
| -424.8%-482pp | 57%+41.7pp | 15.3%— | —— | -8%+8.6pp | ||
| -$0.36-1,900% | $0.02-50.0% | $0.04— | —— | -$0.02+50.0% | ||
| -$678.22K+39.9% | -$1.13M-1,438% | -$73.35K— | —— | -$25.88K+79.8% | ||
| -41.2%+34.3pp | -75.5%-71.1pp | -4.3%— | —— | -1.6%+6.0pp | ||
| -$682.81K+39.7% | -$1.13M-1,347% | -$78.29K+49.6% | -$155.44K-384% | -$32.1K+76.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Evommune 's revenue?
- Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.
- Is Evommune profitable?
- Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.
- What are Evommune 's profit margins?
- Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.
- What is Evommune 's earnings per share?
- Evommune 's diluted EPS over the trailing twelve months is $-0.32.
- Where does Evommune 's income statement data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
